Coffee Drinking and Mortality in Ten European Countries – the EPIC Study

TitleCoffee Drinking and Mortality in Ten European Countries – the EPIC Study
Publication TypeJournal Article
Year of Publication2017
AuthorsGunter MJ, Murphy N, Cross AJ, Dossus L, Dartois L, Fagherazzi G, Kaaks R, Kühn T, Boeing H, Aleksandrova K, Tjønneland A, Olsen A, Overvad K, Larsen SChristian, Cornejo MLuisa Redo, Agudo A, Pérez M J S, Altzibar JM, Navarro C, Ardanaz E, Khaw K-T, Butterworth A, Bradbury KE, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Grioni S, Vineis P, Panico S, Tumino R, Bueno-de-Mesquita B, Siersema P, Leenders M, Beulens JWJ, Uiterwaal CU, Wallström P, Nilsson L M, Landberg R, Weiderpass E, Skeie G, Braaten T, Brennan P, Licaj I, Muller DC, Sinha R, Wareham N, Riboli E
JournalAnnals of Internal Medicine
Date Published07/11
ISBN Number0003-4819<br/>1539-3704
Accession NumberPMC5788283

BACKGROUND: How coffee consumption relates to mortality in diverse European populations, with variable coffee preparation methods and customs, is unclear. OBJECTIVES: To examine whether coffee consumption is associated with all-cause and cause-specific mortality in men and women. DESIGN: Prospective cohort study. SETTING: Ten European countries. PARTICIPANTS: A total of 521,330 men and women enrolled in the European Prospective Investigation into Cancer and Nutrition (EPIC). MAIN OUTCOME MEASURE: Multivariable hazard ratios (HRs) and 95% confidence intervals(CIs) estimated using multivariable Cox proportional hazards models. The association of coffee with serum biomarkers of liver function, inflammation, and metabolic health was evaluated in the EPIC Biomarkers sub-cohort (n=14,800). RESULTS: During a mean follow-up of 16.4 years, 41,693 deaths occurred. Compared with non-consumers, participants in the highest quartile of coffee consumption experienced statistically significant lower all-cause mortality (Men: HR=0.88, 95%CI: 0.82–0.95; P-trend<0.001; Women: HR=0.93, 95%CI: 0.87–0.98; P-trend=0.009). These findings did not vary significantly by country. Inverse associations were observed for digestive disease mortality for men (HR=0.41, 95%CI: 0.32–0.54; P-trend<0.0001) and women (HR=0.60, 95%CI: 0.46–0.78; P-trend<0.0001). Among women only, there was a statistically significant inverse association between coffee and circulatory disease mortality, (HR=0.78, 95%CI: 0.68–0.90; P-trend<0.001), cerebrovascular disease mortality (HR=0.70, 95%CI: 0.55–0.90; P-trend=0.002), and a positive association between coffee and ovarian cancer mortality (HR 1.12, 95% CI: 1.02–1.23 P-trend 0.001). In the EPIC-biomarkers sub-cohort, higher coffee consumption was associated with lower serum alkaline phosphatase, alanine transaminase, aspartate transaminase, and C-reactive protein. LIMITATION: Reverse causality may have led to spurious findings; however, results did not differ following exclusion of participants who died within 8-years of baseline. The study is also limited by a single assessment of coffee drinking habits at baseline. CONCLUSIONS: These results confirm prior findings on the reduced risk of mortality associated with coffee drinking but additionally show that this relationship does not vary by country where coffee preparation and drinking habits may differ. The study also reports novel inverse relationships between coffee drinking and digestive disease mortality.

Short TitleAnn. Intern. Med.